Chinese Japanese Germany Korea


Ciprofloxacin structure
Chemical Name:
Molecular Formula:
Formula Weight:
MOL File:

Ciprofloxacin Properties

Melting point:
storage temp. 
Store at 0-5°C
Soluble in 0.1N HCl at 25mg/ml. Poorly soluble in DMSO
pKa 4.04 (Uncertain)
CAS DataBase Reference
85721-33-1(CAS DataBase Reference)
EPA Substance Registry System
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4- dihydro-4-oxo-7-(1-piperazinyl)- (85721-33-1)


Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26-36-24/25
WGK Germany  2
RTECS  VB1993800
HS Code  29339900
Hazardous Substances Data 85721-33-1(Hazardous Substances Data)

Ciprofloxacin price More Price(8)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 17850 Ciprofloxacin ≥98.0% (HPLC) 85721-33-1 5g-f $65.5 2018-11-20 Buy
Sigma-Aldrich 17850 Ciprofloxacin ≥98.0% (HPLC) 85721-33-1 25g-f $149 2018-11-20 Buy
TCI Chemical C2510 Ciprofloxacin >98.0%(HPLC)(T) 85721-33-1 5g $32 2018-11-22 Buy
TCI Chemical C2510 Ciprofloxacin >98.0%(HPLC)(T) 85721-33-1 25g $103 2018-11-22 Buy
Alfa Aesar J61317 Ciprofloxacin, 98% 85721-33-1 25g $110 2018-11-13 Buy

Ciprofloxacin Chemical Properties,Uses,Production


Ciprofloxacin is a quinolone antibacterial related to recently marketed norfloxacin (10), ofloxacin (2), pefloxacin (2) and enoxacin. It has a broad spectrum of activity against gram-positive and gram-negative bacteria, and is useful in the treatment of urinary and upper respiratory tract infections.

Chemical Properties

White Powder


Bayer (W. Germany)


Fluorinated quinolone antibacterial


ChEBI: A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

brand name

Cipro (Bayer);CIPROBAY.

Antimicrobial activity

It exhibits potent activity against most Enterobacteriaceae, as well as against Acinetobacter spp. (MIC 0.25–1 mg/L), fastidious Gram-negative bacilli such as Mor. catarrhalis (MIC 0.06–0.25 mg/L) and Campylobacter jejuni(MIC 0.12 mg/L). In common with other quinolones, it is active against Bacillus anthracis. Ciprofloxacin is the most active quinolone against Ps. aeruginosa and exhibits good activity in vitro against other non-fermenting Gram-negative bacilli. In-vitro activity against Staph. aureus coagulase-negative staphylococci, Str. pyogenes, Str. pneumoniae and Enterococcus spp. (MIC c. 0.5–2 mg/L) is moderate. Most methicillin-resistant strains of staphylococci are resistant. It has poor activity against anaerobes, but is active against M. tuberculosis, Mycoplasma spp. and intracellular pathogens such as Chlamydia, Chlamydophila and Legionella.

Pharmaceutical Applications

A 6-fluoro, 7-piperazinyl quinolone formulated as the hydrochloride for oral administration and as the lactate for intravenous use.


Oral absorption: 50–80%
Cmax 500 mg oral: 1.5–2 mg/L after 1–2 h
200 mg intravenous (15-min infusion): 3.5 mg/L end infusion
Plasma half-life: 3–4 h
Volume ofdistribution: 3–4 L/kg
Plasma protein binding: 20–40%
After escalating oral doses, mean peak plasma levels increase proportionately with dose. However, accumulation occurs after repeated doses of 500 mg orally or 200 mg intravenously every 12 h: the apparent elimination half-life has been reported to rise to about 6 h after a regimen of 250 mg every 12 h for 6 days. Absorption is delayed, but seems unaffected by food and, in common with other quinolones, is reduced by certain antacids. Co-administration of sucralfate reduces the peak plasma concentrations to undetectable levels in many subjects (mean value from 2 to 0.2 mg/L) and the AUC is reduced to 12% of the value obtained when ciprofloxacin is administered alone. Ferrous sulfate and multivitamin preparations containing zinc significantly reduce absorption, which is also impaired in patients receiving cytotoxic chemotherapy for hematological malignancies. Calculated total bioavailability is 60–70%.
It is widely distributed in body fluids, concentrations in most tissues and in phagocytic cells approximating those in plasma. Concentrations in the CSF, even in the presence of meningitis, are about half the simultaneous plasma levels.
Metabolism and excretion
It is partly metabolized to four metabolites, all but one of which (desethylciprofloxacin) display antibacterial activity. About 95% of a dose can be recovered from feces and urine. Around 40% of an oral and 75% of an intravenous dose appear in the urine over 24 h. Elimination is by both glomerular filtration and tubular secretion (60–70%) and is reduced by concurrently administered probenecid and by renal insufficiency. It is poorly removed by hemodialysis. Part of the administered drug is eliminated in the bile. An enterohepatic cycle results in prolongation of the half-life. The four metabolites are eliminated in the urine and feces at low concentration in comparison to the parent compound.

Side effects

Untoward reactions are uncommon, those encountered being typical of the group. Reactions severe enough to require withdrawal of treatment have occurred in <2% of patients. The most common reactions, gastrointestinal tract disturbances, have been seen in 5% of patients and rashes in about 1%. CNS disturbances typical of quinolones have been reported in 1–2% of patients. Tendinitis and tendon rupture (especially of the Achilles tendon) may occur in a small number of patients and ciprofloxacin should be avoided in patients at risk for these conditions. Potentiation of the action of theophylline and other drugs metabolized by microsomal enzymes may occur. Crystalluria and transient arthralgia have been reported.
In volunteers, dosages of up to 750 mg produced no change in the numbers of fecal streptococci and anaerobes, but did produce a 2.5 × log10 decline in the numbers of enterobacteria, which lasted 1 week. There was no change in the susceptibility of the affected organisms and no overgrowth by resistant strains. As with other quinolones, ciprofloxacin is not recommended for use in children or in pregnant or lactating women.
The drug should be avoided in suspected or confirmed infections caused by Str. pneumoniae. It is inferior to conventional agents and some other fluoroquinolones in the treatment of genital tract infections caused by C. trachomatis.
Ciprofloxacin has also been shown to be effective in the treatment of patients with malignant otitis externa, catscratch disease, prevention of infection in patients undergoing biliary tract surgery, and treatment of biliary tract infections. A topical preparation for use in the treatment of ocular infections is available, but is neither more effective nor safer than established topical agents; it may be indicated for superficial eye infections caused by pathogens resistant to conventional drugs or in patients unable to tolerate standard therapeutic agents.

Ciprofloxacin Preparation Products And Raw materials

Raw materials

Preparation Products

Ciprofloxacin Suppliers

Global( 281)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Hebei Guanlang Biotechnology Co., Ltd.
+86-0311-66562153 whatsapp +8615203118427
+86-0311-66562153 CHINA 414 50
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19947 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3210 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22064 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20743 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32606 55
020-81716319 CHINA 2543 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070; CHINA 3015 60
Hefei TNJ Chemical Industry Co.,Ltd.
86-0551-65418684 18949823763
86-0551-65418684 China 1747 55
Xiamen AmoyChem Co., Ltd
+86 (0)592-605 1114 CHINA 6402 58

View Lastest Price from Ciprofloxacin manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-12-17 Ciprofloxacin
US $7.00 / kg 1kg 99% 100kg career henan chemical co
2019-04-01 Ciprofloxacin
US $1.00 / kg 100g 99.9% 10tons Hebei Jimi Trading Co., Ltd.

85721-33-1(Ciprofloxacin)Related Search:

  • 3-quinolinecarboxylicacid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piper
  • ciloxan
  • ciprobid
  • ciproiv
  • euciprin
  • BAYQ 3939
  • AKOS BBS-00004646
  • 1-cyclopropyl-6-fluoro-7-(1-piperazinyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
  • AKOS 92631
  • 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-
  • Ciprofloxacin (Cipro)
  • Ciflafin
  • Ciprine
  • Ciprobay 100
  • Ciprofloxacillin
  • Enrofloxacin EP Impurity B
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid HCl
  • 1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride
  • 3-Quinolinecarboxylic a
  • Clprofloxacin
  • Ciprofloxaicin USP
  • Ciprofloxacin Solution, 1000ppm
  • Enrofloxacin Impurity 2(Enrofloxacin EP Impurity B)
  • 1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarbox
  • Ciprofloxacin BioChemika, ≥98.0% (HPLC)
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid, Bayq 3939,
  • 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid
  • Ciprofloxacin (base and/or unspecified salts)
  • ciprofloxacin hydrochloride/Ciflox/Ciproxan
  • 1-Cyelopropyl-1,4-dihydro-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
  • Bay 0 9867
  • Baycip
  • Cipmbay
  • Ciprinol
  • Cipro
  • Ciproxin
  • Flociprin:Septicide
  • Velmonit
  • 1,4-Dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)quinoline-3-carboxylic acid
  • 1-Cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
  • CPFX
  • PD-135305
  • Ciprofloxacin (200 mg)H0E3060.998mg/mg(ai)
  • Ciprofloxacin (200 mg)
  • Ciprooxacin (125 mg)
  • C17H18FN3O3
  • C17H18FN3O3xHCl
  • Antibiotics
Copyright 2017 © ChemicalBook. All rights reserved